Cytokine-based immunointervention in the treatment of autoimmune diseases.
Adorini
L
L
BioXell, Via Olgettina 58, 20132 Milan, Italy. luciano.adorini@bioxell.com
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001327:Autoimmune Diseases / Q000276:immunology / Q000628:therapy*; D016207:Cytokines / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007165:Immunosuppression Therapy / Q000379:methods*; D007371:Interferon-gamma / Q000627:therapeutic use; D016753:Interleukin-10 / Q000627:therapeutic use; D018664:Interleukin-12 / Q000276:immunology; D015847:Interleukin-4 / Q000627:therapeutic use; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors; D015375:Receptors, Interleukin-2 / Q000276:immunology; D016212:Transforming Growth Factor beta / Q000627:therapeutic use; D014409:Tumor Necrosis Factor-alpha / Q000276:immunology
D000911:Antibodies, Monoclonal; D016207:Cytokines; D017472:Receptors, Interleukin-1; D015375:Receptors, Interleukin-2; D016212:Transforming Growth Factor beta; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D018664:Interleukin-12; D015847:Interleukin-4; D007371:Interferon-gamma